Health Canada recently approved a new weight loss drug, semaglutide, also known as “Ozempic” or “Wegovy.” Experts refer to it as a “game changer” for its ability to curtail appetite and spur weight loss. In this episode, Medcan’s director of weight management, Dr. David Macklin, a co-author of Canada’s national guidelines for obesity treatment, provides host Shaun Francis with a semaglutide explainer. “We’re in a super exciting stage in my field of medicine,” Dr. Macklin says.
Check out episode highlights and links on our webpage.
